Serum trypsin‐like immunoreactivity in dogs with diabetes mellitus
Abstract Background Concurrent exocrine pancreatic dysfunction and decreased pancreatic organ size are common findings in various stages of human type 1 diabetes mellitus (DM). Exocrine pancreatic insufficiency (EPI) is incompletely described in diabetic dogs. Objective To compare canine trypsin‐lik...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-07-01
|
Series: | Journal of Veterinary Internal Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1111/jvim.16208 |
id |
doaj-e986f21ca5a44de0933ca973886af49b |
---|---|
record_format |
Article |
spelling |
doaj-e986f21ca5a44de0933ca973886af49b2021-07-22T08:15:50ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762021-07-013541713171910.1111/jvim.16208Serum trypsin‐like immunoreactivity in dogs with diabetes mellitusKristen Hamilton0Allison L. O'Kell1Chen Gilor2Small Animal Hospital College of Veterinary Medicine, University of Florida Gainesville Florida USADepartment of Small Animal Clinical Sciences College of Veterinary Medicine, University of Florida Gainesville Florida USADepartment of Small Animal Clinical Sciences College of Veterinary Medicine, University of Florida Gainesville Florida USAAbstract Background Concurrent exocrine pancreatic dysfunction and decreased pancreatic organ size are common findings in various stages of human type 1 diabetes mellitus (DM). Exocrine pancreatic insufficiency (EPI) is incompletely described in diabetic dogs. Objective To compare canine trypsin‐like immunoreactivity (cTLI) of diabetic dogs with that of healthy controls. A secondary aim was to evaluate the correlation between duration of DM and cTLI. Animals Thirty client‐owned diabetic dogs and thirty client‐owned control dogs. Methods Cross‐sectional study. Diabetic and healthy control dogs were included if they had no clinical evidence of pancreatitis and if serum samples obtained after food was withheld were available. Serum cTLI was measured at a reference laboratory and compared between groups. Canine pancreatic lipase immunoreactivity (cPLI) was analyzed concurrently as an indicator of pancreatitis. Results The median cTLI concentration in all diabetic dogs (36.4 μg/L [range, 7.0‐288 μg/L]) did not differ from control dogs (28.7 μg/L [range, 12.8‐58.6 μg/L]) (P = .07; difference −7.8 μg/L [95% Confidence Interval (CI), −23.5 to 0.6 μg/L]). There was still no difference in cTLI between groups after exclusion of dogs with cPLI consistent with pancreatitis (n = 8 diabetic dogs). There was no correlation between cTLI and DM duration in all diabetic dogs (r = −0.07, [95% CI, −0.43 to 0.3], P = .7). Conclusions and Clinical Importance There was no evidence of EPI as evaluated using cTLI in this cohort of diabetic dogs, but concurrent increases in cPLI suggest cTLI might not be the optimal indicator of exocrine pancreatic dysfunction in dogs with DM.https://doi.org/10.1111/jvim.16208dogpancreatic lipase immunoreactivitypancreatitistrypsin‐like immunoreactivity |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kristen Hamilton Allison L. O'Kell Chen Gilor |
spellingShingle |
Kristen Hamilton Allison L. O'Kell Chen Gilor Serum trypsin‐like immunoreactivity in dogs with diabetes mellitus Journal of Veterinary Internal Medicine dog pancreatic lipase immunoreactivity pancreatitis trypsin‐like immunoreactivity |
author_facet |
Kristen Hamilton Allison L. O'Kell Chen Gilor |
author_sort |
Kristen Hamilton |
title |
Serum trypsin‐like immunoreactivity in dogs with diabetes mellitus |
title_short |
Serum trypsin‐like immunoreactivity in dogs with diabetes mellitus |
title_full |
Serum trypsin‐like immunoreactivity in dogs with diabetes mellitus |
title_fullStr |
Serum trypsin‐like immunoreactivity in dogs with diabetes mellitus |
title_full_unstemmed |
Serum trypsin‐like immunoreactivity in dogs with diabetes mellitus |
title_sort |
serum trypsin‐like immunoreactivity in dogs with diabetes mellitus |
publisher |
Wiley |
series |
Journal of Veterinary Internal Medicine |
issn |
0891-6640 1939-1676 |
publishDate |
2021-07-01 |
description |
Abstract Background Concurrent exocrine pancreatic dysfunction and decreased pancreatic organ size are common findings in various stages of human type 1 diabetes mellitus (DM). Exocrine pancreatic insufficiency (EPI) is incompletely described in diabetic dogs. Objective To compare canine trypsin‐like immunoreactivity (cTLI) of diabetic dogs with that of healthy controls. A secondary aim was to evaluate the correlation between duration of DM and cTLI. Animals Thirty client‐owned diabetic dogs and thirty client‐owned control dogs. Methods Cross‐sectional study. Diabetic and healthy control dogs were included if they had no clinical evidence of pancreatitis and if serum samples obtained after food was withheld were available. Serum cTLI was measured at a reference laboratory and compared between groups. Canine pancreatic lipase immunoreactivity (cPLI) was analyzed concurrently as an indicator of pancreatitis. Results The median cTLI concentration in all diabetic dogs (36.4 μg/L [range, 7.0‐288 μg/L]) did not differ from control dogs (28.7 μg/L [range, 12.8‐58.6 μg/L]) (P = .07; difference −7.8 μg/L [95% Confidence Interval (CI), −23.5 to 0.6 μg/L]). There was still no difference in cTLI between groups after exclusion of dogs with cPLI consistent with pancreatitis (n = 8 diabetic dogs). There was no correlation between cTLI and DM duration in all diabetic dogs (r = −0.07, [95% CI, −0.43 to 0.3], P = .7). Conclusions and Clinical Importance There was no evidence of EPI as evaluated using cTLI in this cohort of diabetic dogs, but concurrent increases in cPLI suggest cTLI might not be the optimal indicator of exocrine pancreatic dysfunction in dogs with DM. |
topic |
dog pancreatic lipase immunoreactivity pancreatitis trypsin‐like immunoreactivity |
url |
https://doi.org/10.1111/jvim.16208 |
work_keys_str_mv |
AT kristenhamilton serumtrypsinlikeimmunoreactivityindogswithdiabetesmellitus AT allisonlokell serumtrypsinlikeimmunoreactivityindogswithdiabetesmellitus AT chengilor serumtrypsinlikeimmunoreactivityindogswithdiabetesmellitus |
_version_ |
1721291696606543872 |